New hope: Chemo-Free cocktail targets advanced colorectal cancer
NCT ID NCT07257653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without traditional chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive these drugs as their first treatment. The goal is to see if this approach can delay cancer growth and improve survival while avoiding chemotherapy side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Peer power: could community education boost cancer screening?
- AI eye for colonoscopy: could software catch what doctors miss?
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Could a smartphone photo of stool help detect colon cancer?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?